Aug 25, 2026 · 7 min
Markets punish weak forecasts and uncertain drug data
Intuit Slumps, Spyre Therapeutics Mixed, Dick's Sporting Goods Slides
The episode connects sharp company-specific selloffs with broader questions about consumer demand, biotech economics, and the infrastructure required for growing cities.
- 1Intuit’s weaker full-year profit outlook adds pressure to a stock already down more than 40% this year.
- 2Mixed early-stage rheumatoid arthritis results show how drug efficacy, monotherapy potential, and immunology economics shape biotech valuations.
- 3Dick’s guidance cut exposes weakness across Foot Locker and the sneaker market, while a separate segment examines AI-driven urban planning.
Don't miss
Dick’s Sporting Goods records its sharpest decline after cutting its outlook, while weakness at Foot Locker and in sneakers spreads across athletic brands.
The brief
Tim Stenebeck and Nora Melinda lead a market-movers roundup with Avalon Purnell, beginning with Intuit’s weaker full-year profit forecast and a stock already down more than 40%.
Spire Therapeutics falls after mixed early-stage results for a rheumatoid arthritis treatment, raising questions about monotherapy potential, biologics, patent protection, and immunology profitability.
Dick’s Sporting Goods suffers a record slide after cutting sales and operating-income guidance, with Foot Locker weakness and expected sneaker pressure weighing on Nike and Lululemon.
The episode then shifts from immediate market reactions to long-term urban development, asking how AI and infrastructure blueprints could help cities absorb rapid growth, including Dubai.
Its central contrast is between companies revising expectations downward today and cities trying to design systems for growth that has not yet arrived.
What was said on this episode
12 statements · 6 positive · 5 negative · 1 mixed
Intuit’s performance is less poor than headlines suggest.
“the company's performance isn't nearly as bad as headlines may seem”
Listen at 1:06
Intuit’s results will intensify investor concerns about a SaaS apocalypse.
“the print is definitely going to add fuel to investor concerns about the so-called SaaS. apocalypse.”
Listen at 1:12
AI may cannibalize or change software-as-a-service businesses.
“how exactly is AI going to cannibalize or change the business of software as a service companies?”
Listen at 1:19
Intuit’s near-term outlook appears unfavorable.
“as of now, not looking too promising.”
Listen at 1:37
Spire Therapeutics’ drug missed its internal monotherapy-development threshold.
“the drug kind of fell short of the company's internal bar for developing it as a monotherapy.”
Listen at 2:01
Biologics can delay generic competition through longer patent exclusivity.
“you're going to be able to have a much longer time before generics can come in”
Listen at 2:53
Immunology and inflammation could be highly profitable therapeutic markets.
“what could be a very profitable area of the markets. You likely would want to go towards there.”
Listen at 2:59
Dick’s weak earnings caused Nike, Lululemon, and Deckers to decline.
“that also led a lot of different athletic companies to also drop as well. Nike, Lululemon, Deckers, all lower in today's session”
Listen at 3:35
AI will accelerate processes in smart-city systems.
“AI will allow in the smart city space to compress a lot of things. The speed will change.”
Listen at 4:47
Dubai learned substantially from its sudden population increase.
“Dubai has learned a lot from a sudden increase in population”
Listen at 5:07
Dubai responded effectively to its population increase.
“they reacted very well to it.”
Listen at 5:13
Dubai has a long-term urban-planning vision.
“They have a long-term urban planning vision”
Listen at 5:15
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
Intuit Inc.
TurboTax
Bloomberg L.P.
Spire HealthcareListen to the full episode and explore every guest, topic, and moment on PodLume.